Orthobiologics Market Competitive Landscape & Strategy Framework To 2014 - 2025.

The global orthobiologics market has been segmented based on its applications and product types. On the basis of application, the market been classified into spinal surgery, joint replacement & reconstruction, and trauma surgery. On the basis of product types, the market has been segmented into bone graft substitutes, bone growth stimulators, and viscosupplements. The bone graft substitutes have further been segmented into demoralized bone matrix (DBM), bone morph genic proteins (BMP), bone allografts, and bone autographs. Additionally, viscosupplements has also been further segmented into single injection viscosupplements, 3-injection viscosupplements, and 5-injection viscosupplements.

Over the past few years, the viscosupplements segments held the largest market share for orthobiologics on account of huge demand for knee treatment procedures. It is a very effective pain killer. Viscosupplements are intra-articular injections made of hyaluronic acid which helps in the treatment of osteoarthritis.

Download Free Sample  - https://www.millioninsights.com/industry-reports/orthobiologics-market/request-sample

North America held the majority of the global orthobiologics market in the recent past. The high demand in the market was sustained by increased prevalence of arthritis and obesity in the region, rising demand for the treatment of various diseases such as osteoarthritis and spinal injuries. However, over the next eight years, Asia-Pacific is projected to witness the highest rate of growth for orthobiologics market. This growth will be majorly driven by the Indian and Chinese market on account of a huge number of untapped patient population, economical cost, and medical tourism.

The major industry players operating in the global orthobiologics market include Stryker Corporation, Synthes, Inc., Biomet, Inc., DJO Global, Zimmer Holding, Inc., Medtronic, Inc., and Smith & Nephew, Bacterin International, Inc., DePuySynthes, Inc., Globus Medical, Inc., and Integra LifeSciences Corporation.